Conjugated Estrogens — Discount Pricing
Conjugated Estrogens is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Conjugated Estrogens Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $179.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Conjugated Estrogens
Conjugated Estrogens is a prescription medication. Ask your doctor if Conjugated Estrogens is right for you.
How to Check Conjugated Estrogens Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Conjugated Estrogens at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Hormones
What Conjugated Estrogens is approved for (FDA label)
Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels.
Source: Read the full FDA label on DailyMed. Label effective date: May 30, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Conjugated Estrogens (FDA label)
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. (See WARNINGS, Malignant Neoplasms, Endometrial cancer .) Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia .) The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders .) The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.
Source: FDA prescribing information (DailyMed). Set ID: 87e2da8d-432c-4ed5-67a1-dc26294b2295. SPL document ID: 97a59d56-720c-42fd-86b7-00ad93752452. Label effective date: May 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Conjugated Estrogens (FDA label)
See BOXED WARNINGS , WARNINGS , and PRECAUTIONS . Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account. The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary system Abnormal uterine bleeding/spotting. Dysmenorrhea or pelvic pain. Increase in size of uterine leiomyomata. Vaginitis, including vaginal candidiasis. Change in amount of cervical secretion. Change in cervical ectropion. Ovarian cancer. Endometrial hyperplasia. Endometrial cancer. Breasts Tenderness, enlargement, pain, discharge, galactorrhea.
Source: FDA prescribing information (DailyMed). Set ID: 87e2da8d-432c-4ed5-67a1-dc26294b2295. SPL document ID: 97a59d56-720c-42fd-86b7-00ad93752452. Label effective date: May 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Conjugated Estrogens (FDA label)
Premarin Intravenous therapy should not be used in individuals with any of the following conditions: 1. Undiagnosed abnormal genital bleeding. 2. Known, suspected, or history of breast cancer. 3. Known or suspected estrogen-dependent neoplasia. 4. Active DVT, PE or a history of these conditions. 5. Active arterial thromboembolic disease (for example, stroke and MI) or a history of these conditions. 6. Known anaphylactic reaction and angioedema to Premarin Intravenous therapy. 7. Known liver dysfunction or disease. 8. Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders. 9. Known or suspected pregnancy.
Source: FDA prescribing information (DailyMed). Set ID: 87e2da8d-432c-4ed5-67a1-dc26294b2295. SPL document ID: 97a59d56-720c-42fd-86b7-00ad93752452. Label effective date: May 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.